Lantheus Holdings Inc is expected to report Q3 2026 revenue of $360.82 million and earnings per share of $1.01, with its stock currently trading at $100.46 against an average analyst price target of $107.44. The primary focus for investors is the status of the pending $8 billion acquisition by Curium, which is currently undergoing intensified antitrust review following an FTC Second Request in October.

Investors are also monitoring Pylarify sales performance as the diagnostic agent faces mounting pricing pressure and competition from emerging PSMA-targeted PET imaging products. The anticipated year-over-year revenue decline reflects the recent divestiture of the company's SPECT business and broader market share stabilization for its core oncology portfolio.